Agilon Health, Inc.

NYSE:AGL

Medical - Care Facilities

Healthcare
$90.53 +2.16%

+$2.26 today

Market cap
$1.52B
Beta
3.04
P/E (TTM)
-4.8
EPS (TTM)
-$22.50
52W Low $7.48High $118.25

Volume 0.79M

Average 0.41M

AGL EBITDA Margin

EBITDA as a percentage of revenue.

Agilon Health, Inc.NYSE: AGL

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 2.5%

EBITDA Margin was 2.5% in Q1 FY2026, up 2.0 pp from a year earlier. On a trailing-twelve-month basis it was -5.9%, down 2.2 pp year over year. Over 3 fiscal years it narrowed by 3.2 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 0.7% for the fiscal year ending Dec 2026, up from -6.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
2.5%+13.9 pp QoQ
Last fiscal yearDec 2025
-6.2%-2.6 pp YoY
LTMMar 2026
-5.9%-2.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.0 pp+7.6 pp+5.6 pp
1 year-2.6 pp+6.9 pp+9.5 pp
3 years-3.2 pp+9.5 pp+12.7 pp
5 years+8.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-6.2%
Year-over-year change
-2.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How AGL compares with its peers on the latest reported figures

  • AGL's LTM Mar 2026 EBITDA Margin of -5.9% is the 4th highest of the 6 companies compared; the peer median is 4.9%.
  • Its year-over-year change of -2.2 pp is the 4th highest of 6, against a peer median of +0.4 pp.
  • Over three fiscal years its change of -3.2 pp compares with a peer median of -47.5 pp.
AGL Competitors Peer median
EBITDA Margin for AGL and competitors
Company Period LTM level YoY 3-year change
MCTACharming Medical Limited Class A Ordinary SharesFY202427.6% +4.0 pp—
SLPSimulations Plus, Inc.LTM Feb 202621.5% +0.4 pp-16.1 pp
DHDefinitive Healthcare Corp.LTM Mar 20264.9% +295.3 pp-78.9 pp
AGLAgilon Health, Inc.LTM Mar 2026-5.9% -2.2 pp-3.2 pp
SOPHSOPHiA GENETICS S.A.LTM Mar 2026-81.4% -6.3 pp+87.8 pp
NAKANakamoto Inc.LTM Mar 2026-7060.9% -6900.9 pp-2402.8 pp
ANNXAnnexon, Inc.FY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
DBVTDBV Technologies S.A.FY2025— ——
ENGNenGene Holdings Inc.FY2025— ——
Peer median (excluding AGL) 4.9%+0.4 pp-47.5 pp

Competitors are the stored peer set for AGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.52B2.39B4.32B6.06B5.93B
Cost of Revenue1.46B2.28B4.25B6.06B6.12B
Gross Profit65.74M111.36M69.67M4.84M(188.61M)
Gross Margin4.3%4.7%1.6%0.1%-3.2%
Research & Development00000
Selling, General & Admin427.5M207.79M285.76M268.91M238.54M
Operating Expenses437.99M216.74M301.8M296.97M232.46M
Depreciation & Amortization14.67M13.77M20.16M24.46M28.59M
EBITDA(362.16M)(72.41M)(167.64M)(218.19M)(368.86M)
EBITDA Margin-23.8%-3.0%-3.9%-3.6%-6.2%
Operating Income(372.24M)(105.38M)(232.13M)(292.13M)(421.08M)
Operating Margin-24.5%-4.4%-5.4%-4.8%-7.1%
Interest Income00000
Interest Expense6.15M4.48M6.66M6.18M6.64M
Other Income / Expenses(10.73M)14.71M37.67M43.3M16.98M
Income Before Tax(382.98M)(90.67M)(194.46M)(248.83M)(404.1M)
Pre-Tax Margin-25.2%-3.8%-4.5%-4.1%-6.8%
Income Tax Expense886K1.64M791K1.45M1.25M
Net Income(406.49M)(106.55M)(262.6M)(260.15M)(405.35M)
Net Margin-26.7%-4.5%-6.1%-4.3%-6.8%
EPS (Basic)(27.25)(6.50)(16.00)(15.75)(24.50)
EPS (Diluted)(27.25)(6.50)(16.00)(15.75)(24.50)
Weighted Avg Shares14.92M16.33M16.36M16.44M16.56M
Weighted Avg Shares (Diluted)14.92M16.33M16.36M16.44M16.56M

Agilon Health, Inc.

NYSE:AGL

Intrinsic Alpha fair value

Locked

Current Price

$90.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.